This initial research served as a prospective validation of Efficacy Groupings, and hence power, as a surrogate marker of efficacy in nosocomial pneumonia. Correlates with a Power of 1. Once a patient is identified as having nosocomial pneumonia, drug therapy and associated patient progress will be evaluated daily as per a group of prospectively determined outcomes criteria and documented. For the purposes of this study, patients having pneumonia will be prospectively categorized into one of the three efficacy groups based on the antimicrobial therapy which they receive. Streptococcus pneumoniae Antibiotics may cause a variety of adverse effects and they range from nuisance to life-threatening.
Some antibiotics cause more superinfection than others.
An example of an antibiotic with low superinfection potential is gentamicin. Unfortunately, superinfection is not limited to colitis or vaginitis. Antibiotic-induced secondary pneumonia is a common, although mostly unrecognized, superinfection. Secondary pneumonia almost always involves bacteria or micro-organisms that are more difficult to treat than the original pathogen.